201856-57-7

Basic information

• Product Name: (3R,4S)-tert-Butyl 3-(1-ethoxyethoxy)-2-oxo-4-phenylazetidine-1-carboxylate
• Synonyms: 3-(1-Ethoxyethoxy)-2-oxo-4-phenyl-1-azetidinecarboxylic acid 1,1-dimethylethyl ester;(3r,4s)-tert-butyl 3-(1-ethoxyethoxy)-2-oxo-4-phenylazetidine-1-carboxylate;(3R,4S)-1-AZETIDINECARBOXYLIC ACID-3-(2-ETHOXYETHOXY)-4-PHENYL-2-PHENYL-AZETIDIONE;(3R,4S)-1-t-butoxycarbonyl-3-(2-ethoxyethoxyl)-4-phenyl-2-azetidinone;(3R,4S)-1-T-BUTOXYCARBONYL-3-(2-ETHOXYETHOXYL)-4-PHENYL-2-AZETIDINONE,98+%;SIDE CHAINS OF DOCETAXEL--1;(1-Ethoxyethoxy)-2-oxo-4-phenyl-1-azetidinecarboxylic acid 1,1-dimethyl ethyl ester;(3R,4S)-3-(1-Ethoxyethoxy)-2-oxo-4-phenyl-1-azetidinecarboxylic Acid 1,1-DiMethylethyl Ester
• CAS NO: 201856-57-7
• Molecular Formula: C₁₈H₂₅NO₅
• Molecular Weight: 335.39
• EINECS: 1592732-453-0
• Mol File: 201856-57-7.mol

Chemical Properties

• Boiling Point: 459.592 °C at 760 mmHg
• Flash Point: 231.753 °C
• Appearance: /
• Density: 1.16
• Vapor Pressure: 1.25E-08mmHg at 25°C
• Refractive Index: 1.532
• Storage Temp.: 2-8°C
• PKA: -4.97±0.60(Predicted)
• CAS DataBase Reference: (3R,4S)-tert-Butyl 3-(1-ethoxyethoxy)-2-oxo-4-phenylazetidine-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: (3R,4S)-tert-Butyl 3-(1-ethoxyethoxy)-2-oxo-4-phenylazetidine-1-carboxylate(201856-57-7)
• EPA Substance Registry System: (3R,4S)-tert-Butyl 3-(1-ethoxyethoxy)-2-oxo-4-phenylazetidine-1-carboxylate(201856-57-7)

Safety Data

• Hazardous Substances Data: 201856-57-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
(3R,4S)-tert-Butyl 3-(1-ethoxyethoxy)-2-oxo-4-phenylazetidine-1-carboxylate is used as a reagent in the synthesis of abeo-taxane derivatives, which are known for their broad inhibitory effects against the proliferation of various cancer cell lines, including colon cancer, melanoma, and renal cancer.
(3R,4S)-tert-Butyl 3-(1-ethoxyethoxy)-2-oxo-4-phenylazetidine-1-carboxylate is also used as a reagent in the synthesis of a novel D-ring modified Docetaxel (D494420) analogue. This analogue has demonstrated equipotent cytotoxicity in relation to Paclitaxel (P132500) towards cancer cell lines, indicating its potential as a therapeutic agent in cancer treatment.

InChI:InChI=1/C18H25NO5/c1-6-22-12(2)23-15-14(13-10-8-7-9-11-13)19(16(15)20)17(21)24-18(3,4)5/h7-12,14-15H,6H2,1-5H3

Upstream product

• 132127-31-2 (3R,4S)-3-triisopropylsilyloxy-4-phenylazetidin-2-one 
• 132127-34-5 (3R,4S)-3-hydroxy-4-phenylazetidin-2-one 
• 24424-99-5 di-tert-butyl dicarbonate 
• 201856-48-6 (3R,4S)-3-<((R^*)-1'-ethoxyethyl)oxy>-4-phenyl-2-azetidinone 

Downstream Products

• 1440522-38-2 C₄₇H₄₉NO₁₂ 
• 1440522-40-6 C₄₉H₅₃NO₁₄ 
• 1440522-39-3 C₄₅H₅₃NO₁₃ 
• 1440522-41-7 C₄₇H₅₇NO₁₅ 
• 114915-20-7 Docetaxel 
• 1116070-88-2 2'-(1-ethoxyethyl)-docetaxel 
• 1116070-85-9 C₆₃H₇₃NO₁₉ 
• 1262663-17-1 C₄₉H₆₁NO₁₇ 
• 1262663-08-0 C₄₄H₅₁NO₁₄ 
• 1262663-07-9 C₄₄H₅₁NO₁₄ 
• 1262663-16-0 C₃₇H₄₇NO₁₂ 
• 1262663-15-9 C₃₇H₄₇NO₁₂ 
• 1195007-07-8 2'-EE-10-acetyl-7-Boc-docetaxel 
• 1195007-13-6 2'-EE-7,10-di-Boc-docetaxel 

Relevant articles and documents

A [...] he [...] synthesis process

A [...] he [...] synthesis process, in order to (3 R, 4 S) - 3 - hydroxy - 4 - phenyl - 2 - azetidinone as the starting material, adopts the one-pot synthesis, its first with vinyl ether condensation, with the BOC - anhydride is condensed directly [...] h

Anti-tumor compounds, pharmaceutical compositions, methods for preparation thereof and for treatment

The present invention is directed to novel taxanes useful as chemotherapeutic agents or their precursors. Processes for preparing the novel taxanes include coupling reactions, in the presence of a base, of baccatin of formula (III) or (IV) STR1 with β-lac

Anti-tumor compounds, pharmaceutical compositions, methods for preparation thereof and for treatment

The present invention is directed to novel taxanes useful as chemotherapeutic agents or their precursors. Processes for preparing the novel taxanes include coupling reactions, in the presence of a base, of baccatin of formula (III) or (IV) STR1 with β-lac

A highly efficient route to taxotere by the β-lactam synthon method

Taxotere, a highly promising anticancer drug, is synthesized through an efficient coupling of 7,10-diTroc-10-deacetylbaccatin III with enantiomerically pure (3R,4S)-1-tBOC-3-EEO- 4-phenylazetidin-2-one which is obtained via chiral ester enolate - imine cyclocondensation.